Literature DB >> 18440486

Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?

Tamer Colakoglu1, Sedat Yildirim, Fazilet Kayaselcuk, Tarik Zafer Nursal, Ali Ezer, Turgut Noyan, Hamdi Karakayali, Mehmet Haberal.   

Abstract

BACKGROUND: PTEN is a tumor-suppressor gene located on chromosome 10. Deficient PTEN expression leads to activation of the phosphoinositide 3-kinase (PI3K)/Akt (pAkt) signaling pathway, which may contribute to multiple human cancers. The relation between PTEN expression and Akt activation is still unclear in colorectal cancers and adenomatous polyps. Moreover, PTEN and pAkt expression in relation to demographic, tumoral, and outcome variables remains to be elucidated.
METHODS: PTEN and pAkt expression were evaluated in 76 primary colorectal cancers and 25 adenomatous colorectal polyp tissues using immunohistochemical staining on paraffin-embedded sections. PTEN and pAkt expression were compared with clinicopathologic features of colorectal cancers. The relationship between PTEN and pAkt expression was also investigated.
RESULTS: In colorectal cancers, pAkt expression was found to be significantly higher than polyps (P = .007). On the other hand, PTEN expression was significantly lower in polyps (P <.0001). In colorectal cancer patients, PTEN expression showed a negative correlation with young age, female sex, and left-sided (distal) tumors. On multivariate analysis, low PTEN expression (PTEN loss) was noted as an independent parameter for local recurrence (P = .024). There was significant association between pAkt expression and stage (P = .008), and preoperative serum carcinoembryonic antigen (CEA) levels (P = .017) in colorectal cancers. A negative correlation between PTEN and pAkt expression was found in colon cancer patients (P = .010), whereas no significiant association was found in adenomatous polyps (P = .403). No correlation of PTEN expression or pAkt expression was observed in Kaplan-Meier survival statistics and multivariate analyses for disease-free and overall survival.
CONCLUSIONS: The current study suggests that the PTEN loss-PI3K/pAkt pathway may play an important role in sporadic colon carcinogenesis and that reduced PTEN expression may predict relapse in colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440486     DOI: 10.1016/j.amjsurg.2007.05.061

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  46 in total

1.  No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer.

Authors:  Lynette S Phillips; Cheryl L Thompson; Alona Merkulova; Sarah J Plummer; Thomas C Tucker; Graham Casey; Li Li
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

Review 2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

3.  Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis.

Authors:  Hongyan Qi; Meng Lou; Yuexia Chen; Xiyong Liu; Naiming Chen; Jianzhen Shan; Zhiqiang Ling; Jing Shen; Lijun Zhu; Yun Yen; Shu Zheng; Jimin Shao
Journal:  Tumour Biol       Date:  2015-02-01

4.  Assessment of PI3K/AKT/PTEN signaling pathway activity in colorectal cancer using quantum dot-conjugated antibodies.

Authors:  Dariusz Waniczek; Mirosław Śnietura; Zbigniew Lorenc; Ewa Nowakowska-Zajdel; Małgorzata Muc-Wierzgoń
Journal:  Oncol Lett       Date:  2017-11-10       Impact factor: 2.967

5.  Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.

Authors:  Mayank Jauhri; Akanksha Bhatnagar; Satish Gupta; Yogender Shokeen; Sachin Minhas; Shyam Aggarwal
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

6.  Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Authors:  L S Blaszkowsky; D P Ryan; J Szymonifka; D R Borger; A X Zhu; J W Clark; E L Kwak; H J Mamon; J N Allen; E Vasudev; P C Shellito; J C Cusack; D L Berger; T S Hong
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

7.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

8.  A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways.

Authors:  Xiao Sun; Xiao-Bin Zhuo; Yi-Ping Hu; Xuan Zheng; Qing-Jie Zhao
Journal:  Mol Cell Biochem       Date:  2018-03-12       Impact factor: 3.396

Review 9.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

10.  AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Authors:  Susan C Pitt; Ruth Davis; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.